LB Pharmaceuticals (NASDAQ:LBRX) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of LB Pharmaceuticals (NASDAQ:LBRX) from a strong sell rating to a hold rating in a research note issued to investors on Tuesday morning,Zacks reports.

Several other brokerages have also issued reports on LBRX. Roth Capital lowered shares of LB Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $37.00 to $35.00 in a research report on Monday, October 5th. HC Wainwright reissued a “buy” rating on shares of LB Pharmaceuticals in a research note on Monday, October 12th. Needham & Company LLC assumed coverage on shares of LB Pharmaceuticals in a research report on Friday, October 2nd. They set a “buy” rating and a $68.00 price target for the company. Wall Street Zen lowered shares of LB Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday. Finally, BMO Capital Markets lifted their price objective on LB Pharmaceuticals from $46.00 to $54.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, LB Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $57.40.

LB Pharmaceuticals Stock Performance

LB Pharmaceuticals stock opened at $44.71 on Tuesday. The company’s fifty day moving average price is $40.42 and its 200 day moving average price is $33.27. LB Pharmaceuticals has a 1 year low of $14.40 and a 1 year high of $50.16. The stock has a market capitalization of $1.45 billion, a P/E ratio of -9.68 and a beta of 0.82.

LB Pharmaceuticals (NASDAQ:LBRX) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($1.79) EPS for the quarter, missing the consensus estimate of ($1.61) by ($0.18). Sell-side analysts predict that LB Pharmaceuticals will post -6.05 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in LBRX. Spruce Street Capital LP lifted its holdings in LB Pharmaceuticals by 36.9% in the 1st quarter. Spruce Street Capital LP now owns 1,376,159 shares of the company’s stock valued at $33,645,000 after purchasing an additional 370,566 shares in the last quarter. Candriam S.C.A. purchased a new stake in shares of LB Pharmaceuticals during the third quarter worth $10,949,000. Eversept Partners LP purchased a new stake in shares of LB Pharmaceuticals during the first quarter worth $2,471,000. Janus Henderson Group PLC acquired a new stake in shares of LB Pharmaceuticals in the first quarter valued at about $1,613,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of LB Pharmaceuticals in the second quarter valued at about $1,784,000.

Top LB Pharmaceuticals Stories

These are some of the LBRX stories that stood out recently:

• Positive Sentiment: Zacks Research upgraded LBRX from “strong sell” to “hold,” a less bearish assessment that may provide some support to investor sentiment, though it is not a buy recommendation. Zacks Research recommendations
• Neutral Sentiment: A short-interest update reported zero shares sold short as of November 10, implying no reported short-interest overhang; the article’s description of a “significant increase” conflicts with that zero figure. LB Pharmaceuticals market data
• Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to a loss of $5.98 from $5.47 and lowered its Q4 2026 estimate to a loss of $1.70 from $1.49. It also slightly reduced its Q1 2027 estimate, signaling weaker near-term earnings expectations despite the improvements to later 2027 forecasts. LB Pharmaceuticals analyst coverage

About LB Pharmaceuticals

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for serious neuropsychiatric disorders. Its research focuses on medicines intended to address conditions with significant unmet treatment needs. The company’s lead candidate, LB-102, is an oral investigational drug being studied for schizophrenia. LB Pharmaceuticals has also identified other psychiatric conditions, including bipolar disorder, as potential areas of development. LB-102 has not been approved for commercial use, and its safety and effectiveness have not been established by regulators.